Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat

International Journal of Pharmaceutics

Volumn 202, Issue 1-2, 2000, Pages 97-102

  Mostafavi, S Abolfazl ^a   Foster, Robert T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Enantiomers; Metoprolol; Multiple dose; Pharmacokinetics; Single dose

Indexed keywords

METOPROLOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AREA UNDER CURVE; MALE; METOPROLOL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 0034691641     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00430-0     Document Type: Article

References (18)

1. Appelgren G., Borg K.O., Elofison R., Jhonsson K.A. Binding of adrenergic beta-receptor antagonists to human serum albumin. Acta Pharm. Suec. 11:1974;325-332.
2. Benfield P., Clissold S.P., Brogden R.X. Metoprolol: an update review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischemic heart disease and related cardiovascular disorders. Drugs. 31:1986;376-429.
3. Bhatti M.M., Hussain M.S., Foster R.T. Stereospecific HPLC assay of metoprolol in plasma using a chiral stationary phase. Pharm. Res. 12(9):1995;23.
4. Collste P., Haglud K., Von Bahr C. Plasma levels and effects of metoprolol after single and multiple oral doses. Clin. Pharmacol. Ther. 27:1980;441-449.
5. Cruickshank J.M., Prichard B.N.C. Beta Blockers in Clinical Practice. 2nd edn:1994;354 Churchill Livingstone, New York.
6. Cruickshank J.M., Prichard B.N.C. Beta Blockers in Clinical Practice. 2nd edn:1994;631 Churchill Livingstone, New York.
7. Jordo L, Attman P.O., Aurell M., Johnsson L., Johnsson G., Regardh C.G. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin. Pharmacokinet. 5:1980;169-180.
8. Kendall M.J., John V.A., Quarterman C.P., Welling P.G. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metoprolol. Eur. J. Clin. Pharmacol. 17:1980;87-92.
9. Lennard M.S., Silas J.H., Freeston S., Rainasy L.E., Tucker G.T., Woods H.F. Oxidation phenotype - a major determinant of metoprolol metabolism and response. New Engl. J. Med. 307:1982;1558-1560.
10. Lennard M.S., Tucker G.T., Silas J.H., Freestone S., Ramsay L.E., Woods H.F. Differential stereoselective metabolism of metoprolol in extensive and poor metabolizers. Clin. Pharmacol. Ther. 34:1983;732-737.
11. Lennard M.S., Tucker G.T., Woods H.Y. The polymorphic oxidation of P-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 11:1986;1-17.
12. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (Merit-HF). Lancet. 353:1999;2001-2007.
13. Mostafavi S.A., Foster R.T. Pharmacokinetics of single oral and multiple intravenous and oral administration of acebutolol enantiomers in a rat model. Biopharm. Drug Dispos. 19:1998;425-431.
14. Myers M.G., Thiessen J.J. Metoprolol kinetics and dose response in hypertensive patients. Clin. Pharmacol. Ther. 27:1980;756-762.
15. Quarterman C.P., Kendall M.J., Jack D.B. The effect of age on the pharmacokinetics of metoprolol an its metabolites. Br. J. Clin. Pharmacol. 11:1993;287-294.
16. Regardh C.G., Johnsson G., Jordo L., Solvell L. Comparative bioavilability and effect studies on metoprolol administered as ordinary and slow release tablets in single and multiple doses. Acta Pharmacol. Toxicol. 36((Suppl. V)):1975;45-58.
17. Vermeulen A.M., Belpaire F.M., Smet F.D., Vercruysse L., Bogart M.G. Aging and the pharmacokinetics and metabolism of metoprolol enantiomers in the rat. J. Gerontol. 48:1993;108B-114B.
18. Waagstein F., Wahlqvist L., Andersson B. et al. Metoprolol prevents left ventricular dilation and increase exercise ejection fraction to the same extent in idiopathic and ischemic cardiomyopathy. Eur. Heart J. 19((Suppl.)):1998;307. (Abstract).